

Catalog # 10-5145 Filgotinib

CAS# 1206161-97-8

N-[5-[4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl][1,2,4]triazolo[1,5-a]pyridin-2-yl]-cyclopropanecarboxamide GLPG0634; GS-6034

Lot # X109317

Filgotinib is a potent and selective JAK1 inhibitor (IC₅₀s=10, 28, 810 and 116 nM for JAK1, JAK2, JAK3 and TYK2 respectively.² Displays potent anti-inflammatory activity in various models.^{1,2} Effective as a monotherapy in patients with active rheumatoid arthritis.³ Reverses oncostatin M-mediated inhibition of rat stem Leydig cell differentiation.⁴

- Menet et al. (2014), Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634; J. Med. Chem., 57 9323
- 2) Rompaey et al. (2013), Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases; J. Immunol., **191** 3568
- 3) Kavanaugh et al. (2017), Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomized dose-finding study (DARWIN 2); Ann. Rheum. Dis., **76** 1009
- 4) Wang et al. (2019), Oncostatin M inhibits differentiation of rat stem Leydig cells in vivo and in vitro; J. Cell. Mol. Med., 23 426

PHYSICAL DATA

Molecular Weight: 425.50

NMR: (Conforms)

Solubility: DMSO (up to 15 mg/ml with warming)

Physical Description: Off-white solid

Storage and Stability: Store as supplied desiccated at -20°C for up to 2 years from the date of purchase.

Solutions in DMSO may be stored at -20°C for up to 1 month.

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications.